Luis Angel L. M.
- Country
- Spain
- Department
- Servicio de Oncología
Research Overview
- Efficacy and Safety of PF-08634404 Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase III Randomized, Double-Blind Study Comparing Efficacy and Safety of SB27 and Pembrolizumab in Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 122 of 300 partner sites.
Specializations
Advanced Lung Cancer Treatment
This investigator specializes in treating non-small cell lung cancer (NSCLC) across various stages, with particular focus on advanced and metastatic disease. Their research encompasses innovative therapeutic approaches using targeted and immunotherapy treatments.
- Advanced NSCLC Management
- Metastatic Disease Treatment
- Targeted Therapy Development
Surgical Oncology
The investigator works extensively with resectable lung cancer cases, studying pre-operative and post-operative therapeutic interventions. Their work includes evaluation of neoadjuvant treatments and surgical outcomes in early-stage lung cancer.
- Pre-surgical Therapy
- Post-operative Treatment
- Early-stage NSCLC Management
Molecular and Targeted Therapies
Expertise in treating lung cancers with specific genetic markers, including EGFR mutations and RET fusion-positive NSCLC. The investigator studies novel therapeutic approaches targeting specific molecular pathways.
- Genetic Mutation Analysis
- Personalized Treatment Approaches
- Novel Drug Development
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.